SAN ROCCO THERAPEUTICS
San Rocco Therapeutics offers development of treatments for life-threatening diseases with a special focus on rare diseases, commonly referred to as “orphan diseases.” SRT is developing its portfolio of pharmaceutical products to correct the erroneous gene expression associated with many of these diseases. SRT therapies are currently being developed for hemoglobinopathies and selected cancers.
SAN ROCCO THERAPEUTICS
Industry:
Health Care Hospital
Founded:
1993-01-01
Address:
Tampa, Florida, United States
Country:
United States
Website Url:
http://www.sanroccotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+1 (312) 441-1800
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins Global Site Tag
Similar Organizations
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.sanroccotherapeutics.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.56 K
- Host name: 166.254.208.35.bc.googleusercontent.com
- IP address: 35.208.254.166
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "San Rocco Therapeutics"
San Rocco Therapeutics
Jan 15, 2025 Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin (the protein in red blood cells that carries oxygen). This causes a shortage of …See details»
San Rocco Therapeutics - Crunchbase Company Profile …
Organization. San Rocco Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. San Rocco …See details»
San Rocco Therapeutics | LinkedIn
San Rocco Therapeutics was proud to sponsor the Hands of Hope Sickle Cell Awareness Foundation 10th Annual Walk on Saturday, Sept. 21, 2024, represented by our Project Manager Megan Euker in Tampa ...See details»
San Rocco Therapeutics: About San Rocco Therapeutics
SRT’s business strategy employs gene replacement through gene therapy and gene expression correction through chromatin modification as the basis for treatments for orphan diseases. The …See details»
San Rocco Therapeutics Headquarters and Office Locations
San Rocco Therapeutics is headquartered in Chicago, Jefferson Fulton Building, 218 N Jefferson St #300, United States, and has 4 office locations.See details»
Nextsource | Company Profile | San Rocco Therapeutics
Explore the company profile of San Rocco Therapeutics (sanroccotherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
San Rocco Therapeutics - Craft
Chicago, IL HQ. United States. Jefferson Fulton Building, 218 N Jefferson St #300. New York, NY. United States. 228 Park Ave S #15. Los Angeles, CA. United StatesSee details»
San Rocco Therapeutics (fka Errant Gene Therapeutics)
"The company is conducting lenti-virus based cell therapy trials in SCD and Beta-Thalassemia. It is also exploring the possibility of non-myeloablative conditioning as well as next generation …See details»
San Rocco Therapeutics | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
San Rocco Therapeutics: History and Timeline
Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin (the protein in red blood cells that carries oxygen). This causes a shortage of red blood cells and low levels of oxygen in the …See details»
Drug pipelines, Patents, Clinical trials - Synapse - Patsnap
Explore San Rocco Therapeutics with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Hemic and Lymphatic Diseases ...See details»
San Rocco Therapeutics Logo & Brand Assets (SVG, PNG and …
Sanroccotherapeutics.com. Brand Logos View all. Logo. SVG. Logo. SVG. About San Rocco Therapeutics. Description. San Rocco Therapeutics is a pioneering brand committed to …See details»
Science & Technology - San Rocco Therapeutics
SRT’s strategy for the development of new therapeutics for life threatening diseases is based upon the concept of “genetic medicine” in which disease is viewed in the context of the …See details»
San Rocco Therapeutics Scientific Founder Dr. Michel Sadelain is ...
May 17, 2021 TAMPA, Fla.--(BUSINESS WIRE)--San Rocco Therapeutics (SRT), formerly Errant Gene Therapeutics, applauds Dr. Michel Sadelain, MD, PhD, Director of Memorial …See details»
San Rocco Therapeutics, LLC (“SRT”) Pushes Clinical Trial for a ...
Apr 12, 2022 San Rocco Therapeutics, LLC (“SRT”) Pushes Clinical Trial for a Curative Treatment for Beta-Thalassemia and Sickle Cell DiseaseSee details»
The story of San Rocco Therapeutics with Founder Patrick Girondi ...
Https://lnkd.in/dtcmBUG4 The Story of San Rocco Therapeutics #sanroccotherapeutics #genetherapy #SickleCellDisease #ThalassemiaSee details»
Product Pipeline - San Rocco Therapeutics
San Rocco Therapeutics’ strong intellectual property position is the result of acquisition and academic collaborations. The Company’s foremost objective is the rapid commercialization of …See details»
#sanroccotherapeutics #sicklecelldisease #sicklecellawareness # ...
#sanroccotherapeutics is proud to sponsor the Hands of Hope - Sickle Cell Awareness Foundation Inc. Fashion show Save the date: March 15, 2025 #SickleCellDisease …See details»
San Rocco Therapeutics : Scientific Founder Dr. Michel Sadelain is ...
May 17, 2021 San Rocco Therapeutics , formerly Errant Gene Therapeutics, applauds Dr. Michel Sadelain, MD, PhD, Director of Memorial Sloan Kettering’s Center for Cell Engineering …See details»
New study results reinforce Tagrisso as the backbone therapy for …
10 hours ago New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as …See details»